Abstract
Over the past two decades, large population genotyping studies have delivered a better understanding of disease, an expanded pipeline of therapeutic targets and new diagnostic/predictive tests to improve health and wellness. Today's most comprehensive microarrays can provide over 5 million single nucleotide variants (SNVs) at a cost of approximately $0.001 per genotype ($450 / sample). Our Next-Generation Genotyping (NGG) approach enables the sequence-based genotyping of more than 37 million genetic markers at a cost of less than $0.000002 / genotype (less than $80/sample).